HN2006042221A - Derivados de piridina para el tratamiento del crecimiento celular anormal - Google Patents

Derivados de piridina para el tratamiento del crecimiento celular anormal

Info

Publication number
HN2006042221A
HN2006042221A HN2006042221A HN2006042221A HN2006042221A HN 2006042221 A HN2006042221 A HN 2006042221A HN 2006042221 A HN2006042221 A HN 2006042221A HN 2006042221 A HN2006042221 A HN 2006042221A HN 2006042221 A HN2006042221 A HN 2006042221A
Authority
HN
Honduras
Prior art keywords
treatment
cellular growth
abnormal cellular
piridine derivatives
piridine
Prior art date
Application number
HN2006042221A
Other languages
English (en)
Inventor
Thomas Arcari Joel
Kumar Bhattacharya Samit
Douglas Brosius Arthur
Joseph Luzzio Michael
Louise Nelson Kendra
Pan Gonghua
Alfred Southers James Jr
Gregory Wishka Donn
Xiao Jun
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN2006042221A publication Critical patent/HN2006042221A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVOS DERIVADOS DE PIRIDINA QUE SON UTILES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL, TAL CONO EL CANCER EN MAMIFEROS .
HN2006042221A 2005-12-21 2006-12-20 Derivados de piridina para el tratamiento del crecimiento celular anormal HN2006042221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
HN2006042221A true HN2006042221A (es) 2010-01-18

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2006042221A HN2006042221A (es) 2005-12-21 2006-12-20 Derivados de piridina para el tratamiento del crecimiento celular anormal

Country Status (30)

Country Link
US (1) US7820648B2 (es)
EP (1) EP1966207A2 (es)
JP (1) JP4332590B2 (es)
KR (1) KR101060051B1 (es)
CN (1) CN101346380B (es)
AP (1) AP2008004488A0 (es)
AR (1) AR058399A1 (es)
AU (1) AU2006327871A1 (es)
BR (1) BRPI0620324A2 (es)
CA (1) CA2634646C (es)
CR (1) CR10095A (es)
DO (1) DOP2006000289A (es)
EA (1) EA014551B1 (es)
EC (1) ECSP088563A (es)
GT (1) GT200600517A (es)
HN (1) HN2006042221A (es)
IL (1) IL191555A0 (es)
MA (1) MA30075B1 (es)
ME (1) MEP0908A (es)
NL (1) NL2000375C2 (es)
NO (1) NO20082338L (es)
PE (1) PE20071138A1 (es)
RS (1) RS20080272A (es)
SV (1) SV2008002969A (es)
TN (1) TNSN08270A1 (es)
TW (1) TW200736258A (es)
UA (1) UA89123C2 (es)
UY (1) UY30051A1 (es)
WO (1) WO2007072158A2 (es)
ZA (1) ZA200804488B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
CA2669111C (en) 2006-10-23 2016-04-12 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
EA016679B1 (ru) 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Сульфониламидные производные для лечения аномального роста клеток
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
KR101695501B1 (ko) 2008-06-17 2017-01-11 아스트라제네카 아베 피리딘 화합물
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
RU2013147417A (ru) 2011-03-24 2015-04-27 Кемилиа Аб Новые производные пиримидина
EP2788345B1 (en) 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
RU2014130214A (ru) 2011-12-23 2016-02-10 Целльзом Лимитид Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
US20240025887A1 (en) * 2021-01-07 2024-01-25 Ontario Institute For Cancer Research (Oicr) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
CN1717396A (zh) * 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004067516A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
MXPA06011890A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para tratar el crecimiento celular anomalo.
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
WO2007072158A2 (en) 2007-06-28
CR10095A (es) 2008-07-17
TW200736258A (en) 2007-10-01
ZA200804488B (en) 2009-05-27
AP2008004488A0 (en) 2008-06-30
EA014551B1 (ru) 2010-12-30
RS20080272A (en) 2009-07-15
GT200600517A (es) 2007-09-13
WO2007072158A3 (en) 2007-12-27
NL2000375A1 (nl) 2007-06-25
NL2000375C2 (nl) 2008-01-03
BRPI0620324A2 (pt) 2011-11-08
UY30051A1 (es) 2007-07-31
CA2634646C (en) 2012-04-10
UA89123C2 (ru) 2009-12-25
NO20082338L (no) 2008-06-25
JP2009520807A (ja) 2009-05-28
KR20080077026A (ko) 2008-08-20
DOP2006000289A (es) 2007-07-31
IL191555A0 (en) 2008-12-29
KR101060051B1 (ko) 2011-08-29
WO2007072158A8 (en) 2008-08-14
AU2006327871A1 (en) 2007-06-28
CA2634646A1 (en) 2007-06-28
TNSN08270A1 (fr) 2009-10-30
JP4332590B2 (ja) 2009-09-16
CN101346380B (zh) 2012-02-29
EA200801287A1 (ru) 2008-10-30
SV2008002969A (es) 2010-08-17
US7820648B2 (en) 2010-10-26
EP1966207A2 (en) 2008-09-10
MA30075B1 (fr) 2008-12-01
MEP0908A (xx) 2010-02-10
ECSP088563A (es) 2008-07-30
US20080234303A1 (en) 2008-09-25
AR058399A1 (es) 2008-01-30
CN101346380A (zh) 2009-01-14
PE20071138A1 (es) 2007-12-29

Similar Documents

Publication Publication Date Title
HN2006042221A (es) Derivados de piridina para el tratamiento del crecimiento celular anormal
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
CU23813A3 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
HN2003000257A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos.
GT200200273A (es) Moleculas pequeñas para el tratamiento del crecimiento celular anormal
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
GT200900263A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer
HN2007015177A (es) Derivados de triazolopirazina
PA8740901A1 (es) Compuestos organicos
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
CR20110496A (es) Biespecificos anticuerpos anti-her
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CR8749A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
UY32125A (es) Compuestos novedosos como ligandos de receptores de canabinoides
CR11098A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.